These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 12506151)

  • 21. Functional status, time to transplantation, and survival benefit of kidney transplantation among wait-listed candidates.
    Reese PP; Shults J; Bloom RD; Mussell A; Harhay MN; Abt P; Levine M; Johansen KL; Karlawish JT; Feldman HI
    Am J Kidney Dis; 2015 Nov; 66(5):837-45. PubMed ID: 26162652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic Evaluation of Left Ventricular Assist Devices for Patients With End Stage Heart Failure Who Are Ineligible for Cardiac Transplantation.
    Chew DS; Manns B; Miller RJH; Sharma N; Exner DV
    Can J Cardiol; 2017 Oct; 33(10):1283-1291. PubMed ID: 28941608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative survival and cost-effectiveness of advanced therapies for end-stage heart failure.
    Long EF; Swain GW; Mangi AA
    Circ Heart Fail; 2014 May; 7(3):470-8. PubMed ID: 24563450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of haemodialysis and peritoneal dialysis for patients with end-stage renal disease in Singapore.
    Yang F; Lau T; Luo N
    Nephrology (Carlton); 2016 Aug; 21(8):669-77. PubMed ID: 26566750
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In Denmark kidney transplantation is more cost-effective than dialysis.
    Jensen CE; Sørensen P; Petersen KD
    Dan Med J; 2014 Mar; 61(3):A4796. PubMed ID: 24814915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The expanded criteria donor dilemma in cadaveric renal transplantation.
    Schnitzler MA; Whiting JF; Brennan DC; Lin G; Chapman W; Lowell J; Boxerman S; Hardinger KL; Kalo Z
    Transplantation; 2003 Jun; 75(12):1940-5. PubMed ID: 12829891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Access to the waiting list and renal transplantation].
    Hourmant M; de Cornelissen F; Brunet P; Pavaday K; Assogba F; Couchoud C; Jacquelinet C;
    Nephrol Ther; 2013 Sep; 9 Suppl 1():S139-66. PubMed ID: 24119579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cost-effectiveness analysis of treatment for end-stage renal disease].
    Asgeirsdóttir TL; Asmundsdóttir G; Heimisdóttir M; Jónsson E; Pálsson R
    Laeknabladid; 2009 Nov; 95(11):747-53. PubMed ID: 19996463
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psychosocial variables are associated with being wait-listed, but not with receiving a kidney transplant in the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Szeifert L; Bragg-Gresham JL; Thumma J; Gillespie BW; Mucsi I; Robinson BM; Pisoni RL; Disney A; Combe C; Port FK
    Nephrol Dial Transplant; 2012 May; 27(5):2107-13. PubMed ID: 22058174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic Decision Model for First-Time Traumatic Patellar Dislocations in Adolescents.
    Nwachukwu BU; So C; Schairer WW; Shubin Stein BE; Strickland SM; Green DW; Dodwell ER
    Am J Sports Med; 2017 Aug; 45(10):2267-2275. PubMed ID: 28463547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant.
    Wolfe RA; Ashby VB; Milford EL; Ojo AO; Ettenger RE; Agodoa LY; Held PJ; Port FK
    N Engl J Med; 1999 Dec; 341(23):1725-30. PubMed ID: 10580071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renal transplantation in elderly patients older than 70 years of age: results from the Scientific Registry of Transplant Recipients.
    Rao PS; Merion RM; Ashby VB; Port FK; Wolfe RA; Kayler LK
    Transplantation; 2007 Apr; 83(8):1069-74. PubMed ID: 17452897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation.
    Haasova M; Snowsill T; Jones-Hughes T; Crathorne L; Cooper C; Varley-Campbell J; Mujica-Mota R; Coelho H; Huxley N; Lowe J; Dudley J; Marks S; Hyde C; Bond M; Anderson R
    Health Technol Assess; 2016 Aug; 20(61):1-324. PubMed ID: 27557331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cost-effectiveness of interventions for end-stage renal disease].
    Arredondo A; Rangel R; de Icaza E
    Rev Saude Publica; 1998 Dec; 32(6):556-65. PubMed ID: 10349148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.
    Jones-Hughes T; Snowsill T; Haasova M; Coelho H; Crathorne L; Cooper C; Mujica-Mota R; Peters J; Varley-Campbell J; Huxley N; Moore J; Allwood M; Lowe J; Hyde C; Hoyle M; Bond M; Anderson R
    Health Technol Assess; 2016 Aug; 20(62):1-594. PubMed ID: 27578428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Why are cadaveric renal transplants so hard to find in Japan? An analysis of economic and attitudinal aspects.
    Ohi G; Hasegawa T; Kumano H; Kai I; Takenaga N; Taguchi Y; Saito H; Ino T
    Health Policy; 1986; 6(3):269-78. PubMed ID: 10311723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Registration on the renal transplantation waiting list and mortality on dialysis: an analysis of the French REIN registry using a multi-state model.
    Beuscart JB; Pagniez D; Boulanger E; Duhamel A
    J Epidemiol; 2015; 25(2):133-41. PubMed ID: 25721069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard.
    Lee CP; Chertow GM; Zenios SA
    Value Health; 2009; 12(1):80-7. PubMed ID: 19911442
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic evaluation of palliative management versus peritoneal dialysis and hemodialysis for end-stage renal disease: evidence for coverage decisions in Thailand.
    Teerawattananon Y; Mugford M; Tangcharoensathien V
    Value Health; 2007; 10(1):61-72. PubMed ID: 17261117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom.
    Bernard L; Mendelssohn D; Dunn E; Hutchison C; Grima DT
    J Med Econ; 2013; 16(1):1-9. PubMed ID: 22857538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.